These guidelines provide an update on the management of chronic obstructive pulmonary disease (COPD) in Singapore and take into account the new evidence which has emerged since the publication of the previous guidelines in 2006.
Commonly used abbreviations
The following is a list of abbreviations commonly used in this set of guidelines (arranged in alphabetical order), and a description of what they represent. COPD assessment test chronic obstructive pulmonary disease forced expiratory volume in one second change in FEV 1 (difference between post-bronchodilator and pre-bronchodilator FEV 1 ) forced expiratory ratio forced vital capacity (volume of lungs from full inspiration to forced maximal expiration) Global Initiative for Chronic Obstructive Lung Disease inhaled corticosteroid long-acting beta 2 agonist long-acting muscarinic receptor antagonist partial pressure arterial oxygen peak expiratory flow short-acting beta 2 agonist short-acting muscarinic receptor antagonist
The following flowchart illustrates the treatment algorithm for a suspected case of COPD (page numbers are from the full CPG).
Population prevalence & risk factors of COPD
The Burden of Obstructive Lung Disease (BOLD) studies showed COPD among adults aged 40 and above varied widely among 12 countries, ranging from 11.4% to 26.1%. Although the higher prevalence of COPD among smokers than non-smokers is well established, it is important to note that about 3%-10% of non-smokers also have COPD, indicating that non-smoking risk factors are also important.
Non-smoker risk factors include the use of biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory tract infections during childhood, outdoor air pollution and poor socioeconomic status. Data from the Singapore Longitudinal Ageing Studies show similar prevalence and pattern of risk factors. The prevalence of COPD shows no gender differences, but is higher among older people and among smokers.
Assessing and monitoring COPD

Diagnosis of COPD
The characteristic symptoms of COPD are persistent and progressive exertional dyspnoea, cough, sputum production, wheezing, and chest tightness that can vary from day to day. There should be a positive history of exposure to risk factors of tobacco smoke, smoke from home cooking and occupational dust.
GPP Patients who are older than 40 years of age and who are current or ex-smokers should undertake spirometry if they answer 'yes' to any one of the following questions: A FEV 1 /FVC ratio < 0.7 and a ΔFEV 1 < 200 mL after bronchodilators treatment demonstrates expiratory airflow limitation. Such a result combined with the presence of characteristic symptoms and positive risk factor exposure is highly suggestive of COPD.
Assessment of COPD
Clinical assessment of the COPD patient should include a thorough history (i.e. occupational or environmental exposure to lung irritants, COPD signs and symptoms, complications, exacerbations) and physical examination.
The goals of COPD assessment are to determine disease severity, its impact on the patient's health status and the risk of future events such as exacerbations, hospitalisations or death in order to guide treatment.
A combined approach to COPD assessment considers the following aspects of the disease ( Fig. 1 COPD often coexists with other diseases that may have a significant impact on prognosis. The presence of comorbidities should not alter COPD treatment, and comorbidities should be treated as if the patient did not have COPD.
Role of chest X-ray
Chest X-rays are not diagnostic of COPD but are valuable in assessing comorbidities and excluding conditions, such as lung cancer and pulmonary tuberculosis -symptoms of which are similar to that of COPD.
D
A chest X-ray should be done when a diagnosis of COPD is suspected.
(Grade D, Level 4, CPG pg. 23)
Monitoring of COPD
GPP COPD patients should be followed up every 3-6 months.
The CAT score should be used at each visit to track symptoms related to COPD. Routine yearly chest X-rays are not required.
(CPG pg. 24)
If a patient reports acute or progressive worsening of respiratory symptoms, the following possibilities will need to be considered: (1) The patient is experiencing a COPD exacerbation. (2) The COPD severity is worsening. (3) There is a superimposed acute/subacute respiratory condition, e.g. pneumonia, pneumothorax, pulmonary tuberculosis (PTB), lung cancer. (4) The comorbid conditions, e.g. ischaemic heart disease (IHD) and heart failure, are unstable.
Smoking cessation
A
Smoking cessation is a vital intervention in COPD which will preserve lung function and improve survival. It is recommended for all patients with COPD. 
Pharmacological treatment
The goals of pharmacotherapy in COPD are as follows:
(1) Relieve, reduce and abolish symptoms where possible. When treatment is given via inhalational route, choice of device will depend on availability, cost and patient's ability. Use of a spacer with metered dose inhaler devices may overcome coordination problems and improve drug delivery.
Bronchodilators
In choosing among treatment options for patients, decisionmaking can be guided by choosing the appropriate drug class according to GOLD guidelines.
A
Short-acting bronchodilators are prescribed on an asneeded basis and should be the initial empirical treatment for the relief of breathlessness and exercise limitation. However, careful monitoring for side effects and drug interactions is needed in view of its narrow therapeutic index. 
Management of acute exacerbations
An exacerbation is a sustained worsening of the patient's symptoms from their usual stable state which is beyond normal day-to-day variations, and is acute in onset. Exacerbations are defined as mild when there is a change of inhaled treatment by the patient, moderate when exacerbations of respiratory symptoms require medical intervention including a short course of antibiotic and/or oral steroids, and severe when exacerbations of respiratory symptoms require hospitalisation. The diagnosis of an exacerbation is made clinically and does not depend on the results of investigations. The goals of treatment for an acute exacerbation of COPD are to minimise the impact of the current exacerbation and prevent the development of subsequent exacerbations.
D
Sending sputum samples for culture in primary care is not recommended. The management algorithm for an acute exacerbation is described in Fig. 3 . 
Pharmacological management of an acute exacerbation
Referral to emergency department
The majority of patients with COPD exacerbations can be successfully managed as outpatients. The indications for hospital assessment and factors which determine site of care are listed in Table 2 . Patients with severe exacerbations who fail to respond to oxygen and pharmacotherapy may need ventilator support, which may be invasive or non-invasive. Mechanical ventilation should be performed in a setting with local expertise such as an intensive care unit (ICU). The indications for admission to ICU are listed in Table 3 . Non-invasive ventilation A Non-invasive ventilation should be used as the treatment of choice for persistent hypercapnic ventilatory failure during exacerbations of COPD despite optimal medical therapy. 
GPP
D
Palliative care
Palliative care aims to prevent and relieve suffering by controlling symptoms and supporting patients, especially those suffering from advanced COPD or life-threatening exacerbations, and their families so that the best possible quality of life may be achieved. 
Clinical quality improvement
The following clinical quality indicators are recommended. Healthcare providers may use these indicators to monitor their practice and to better gauge their quality of care. Recommended best practice based on the clinical experience of the guideline development group.
